acid ethyl ester] is a novel anticonvulsant compound that is now in clinical phase II development. It has previously been shown to enhance currents generated by KCNQ2/3 K ϩ channels when expressed in Chinese hamster ovary (CHO) cells (Main et al., 2000; Wickenden et al., 2000) . In the present study, we have compared the actions of retigabine on KCNQ2/3 currents with those on currents generated by other members of the KCNQ family (homomeric KCNQ1, KCNQ2, KCNQ3, and KCNQ4 channels) expressed in CHO cells and on the native M current in rat sympathetic neurons [thought to be generated by KCNQ2/3 channels (Wang et al., 1998) ]. Retigabine produced a hyperpolarizing shift of the activation curves for KCNQ2/3, KCNQ2, KCNQ3, and KCNQ4 currents with differential potencies in the following order: KCNQ3 Ͼ KCNQ2/3 Ͼ KCNQ2 Ͼ KCNQ4, as measured either by the maximum hyperpolarizing shift in the activation curves or by the EC 50 values. In contrast, retigabine did not enhance cardiac KCNQ1 currents. Retigabine also produced a hyperpolarizing shift in the activation curve for native M channels in rat sympathetic neurons. The retigabine-induced current was inhibited by muscarinic receptor stimulation, with similar agonist potency but 25% reduced maximum effect. In unclamped neurons, retigabine produced a hyperpolarization and reduced the number of action potentials produced by depolarizing current injections, without change in action potential configuration.
Retigabine [D-23129; N-(2-amino-4-(4-fluorobenzylamino) phenyl) carbamic acid ethyl ester] is a novel anticonvulsant compound that is now in clinical phase II development. It has previously been shown to enhance currents generated by KCNQ2/3 K ϩ channels when expressed in Chinese hamster ovary (CHO) cells (Main et al., 2000; Wickenden et al., 2000) . In the present study, we have compared the actions of retigabine on KCNQ2/3 currents with those on currents generated by other members of the KCNQ family (homomeric KCNQ1, KCNQ2, KCNQ3, and KCNQ4 channels) expressed in CHO cells and on the native M current in rat sympathetic neurons [thought to be generated by KCNQ2/3 channels (Wang et al., 1998) ]. Retigabine produced a hyperpolarizing shift of the activation curves for KCNQ2/3, KCNQ2, KCNQ3, and KCNQ4 currents with differential potencies in the following order: KCNQ3 Ͼ KCNQ2/3 Ͼ KCNQ2 Ͼ KCNQ4, as measured either by the maximum hyperpolarizing shift in the activation curves or by the EC 50 values. In contrast, retigabine did not enhance cardiac KCNQ1 currents. Retigabine also produced a hyperpolarizing shift in the activation curve for native M channels in rat sympathetic neurons. The retigabine-induced current was inhibited by muscarinic receptor stimulation, with similar agonist potency but 25% reduced maximum effect. In unclamped neurons, retigabine produced a hyperpolarization and reduced the number of action potentials produced by depolarizing current injections, without change in action potential configuration.
Key words: potassium channels; KCNQ channels; M channels; sympathetic neurons; retigabine; anti-convulsant M-type potassium (K ϩ ) currents (I K(M) ) are a species of subthreshold voltage-gated K ϩ current that serve to stabilize the membrane potential and control neuronal excitability. They were first described in sympathetic neurons but have subsequently been reported in various other neurons, including hippocampal and cortical pyramidal cells (for review, see Brown, 1988; Marrion, 1997) .
Recent evidence suggests that the native M channels in rat sympathetic neurons are composed of a heteromeric assembly of KCNQ2 and KCNQ3 K ϩ channel subunits (Wang et al., 1998; Hadley et al., 2000; Selyanko et al., 2000b; Shapiro et al., 2000) . These are K ϩ channel gene products that are widely distributed in the nervous system, mutations of which give rise to a form of congenital epilepsy termed benign familial neonatal convulsions (Biervert et al., 1998; Charlier et al., 1998; Singh et al., 1998 ; for review, see Rogawski, 2000; Jentsch, 2000) . This implies that M channels may assist in controlling seizure discharges and that drugs that enhance M channel activity might be effective anti-epileptic agents. In accordance with this, the anti-convulsant drug retigabine [D-23129; N-(2-amino-4-(4-fluorobenzylamino) -phenyl) carbamic acid ethyl ester] Tober et al., 1996) has been reported to open K ϩ channels in NG108 -15 neuroblastomaglioma hybrid cells (Rundfeldt, 1997) and to enhance currents through expressed heteromeric KCNQ2/3 channels, in part by shifting their voltage sensitivity to more hyperpolarized membrane potentials (Main et al., 2000; Rundfeldt and Netzer, 2000; Wickenden et al., 2000) .
T wo questions arise, however, concerning the effect of retigabine. First, KC NQ2 and KC NQ3 are members of a larger family of homologous K ϩ channels comprising, in addition, a subunit (KC NQ1) of the cardiac delayed rectifier current (Barhanin et al., 1996; Sanguinetti et al., 1996) , a subunit (KC NQ4) present in the auditory system (Kubisch et al., 1999; K harkovets et al., 2000) , and another recently identified subunit (KC NQ5) widely distributed in the C NS and PNS (Lerche et al., 2000; Schroeder et al., 2000) . All of these subunits, when expressed as homomultimers, generate "M-like" currents as defined kinetically and pharmacologically (Hadley et al., 2000; Selyanko et al., 2000b; Schroeder et al., 2000) . It is not yet known whether they are all equally sensitive to retigabine. Second, it has yet to be established whether retigabine affects native neuronal M currents in the same way that it affects expressed KC NQ2/3 channels. Accordingly, in the present experiments, we have compared the action of retigabine on heteromeric KC NQ2/3 currents expressed in mammalian CHO cells with its action on expressed homomeric KC NQ1, KC NQ2, KC NQ3, and KC NQ4 currents, on the one hand, and on native M currents in rat sympathetic neurons on the other.
While this work was in progress, Wickenden et al. (2001) reported that retigabine also enhances currents through concatameric KCNQ3/5 channels in CHO cells.
MATERIALS AND METHODS
Chinese hamster ovar y cell culture and transfection. Chinese Hamster Ovary (CHO) cells stably transfected with cDNA encoding human M 1 muscarinic receptors (Mullaney et al., 1993) were cultured in ␣-M EM supplemented with 10% fetal calf serum, 1% L-glutamine, and 1% penicillin /streptomycin. C ells were split when confluent and plated onto 35 mm dishes. C ells were left at 37°C and 5% C O 2 for 1 d before transfection using LipofectAmine Plus (Life Technologies, Gaithersburg, MD) according to the manufacturer's recommendations. Plasmids containing KC NQ and CD8 cDNAs, and driven by the cytomegalovirus promoter, were cotransfected in a ratio of 10:1. For expression of heteromultimers, equal amounts of KC NQ2 and KC NQ3 cDNAs were used. Successf ully transfected cells were identified by adding CD8-binding Dynabeads (Dynal, Great Neck, N Y) before electrophysiological recording.
Ganglion cell culture. Primary cultures of neurons were prepared from superior cervical ganglia (SCG) from 17-d-old Sprague Dawley rats, using a standard enzymatic dissociation procedure, as f ully described elsewhere (Delmas et al., 1998b) . Rats were killed by C O 2 inhalation and decapitated, according to the U.K . Animals (Scientific Procedures) Act 1986. Ganglia were dissected from the carotid bif urcation, and the surrounding sheath was removed. Each ganglion was cut into several pieces with iridectomy scissors and incubated at 37°C in collagenase (500 U/ml and bovine serum albumin 6 mg /ml) and then in trypsin (1 mg /ml with 6 mg /ml BSA). After trituration the cells were centrif uged, and the pellet was resuspended in culture medium (L -15 medium supplemented with 10% fetal bovine serum, 24 mM NaHC O 3 , 38 mM glucose, 50 U/ml penicillin and streptomycin, 25 ng /ml nerve growth factor). After the dissociated cells were plated onto laminin-coated 35 mm plastic Petri dishes, the cells were kept in a 37°C incubator with 5% C O 2 .
Electrophysiolog ical recording. Currents in CHO cells and SCG neurons were recorded using the amphotericin-B perforated-patch technique (Rae et al., 1991) . Patch electrodes (2-3 M⍀) were filled by dipping the tip for 40 sec into the appropriate filtered internal solution, and the pipette was then backfilled with the internal solution containing 0.1-0.2 mg /ml amphotericin-B. After permeabilization, access resistances were generally Ͻ15 M⍀. The recording electrodes had resistance of 2-3 M⍀ when filled with internal solution.
Recordings from CHO cells were made at room temperature 1-2 d after transfection. No appreciable current was noticed in untransfected CHO cells. The extracellular solution consisted of (in mM): NaC l 144, KC l 2.5, C aC l 2 2, MgC l 2 0.5, H EPES 5, and glucose 10; pH 7.4 with Tris base. To record tail currents at Ϫ120 mV (for the purpose of construction of activation curves), external KC l was raised to 25 mM; the increase in osmolarity was compensated by reducing the concentration of NaC l to 121.5 mM. The internal (pipette) solution contained (in mM): K ϩ acetate 80, KC l 30, H EPES 40, MgC l 2 3, EGTA 3, C aC l 2 1; pH 7.4 with KOH.
K ϩ and C a 2ϩ current recordings in SCG neurons were as described (Delmas et al., 2000) . Briefly, SCG neurons were perf used with an external solution consisting of (in mM): NaC l 120, KC l 3, H EPES 5, NaHC O 3 23, glucose 11, MgC l 2 1.2, C aC l 2 2.5, tetrodotoxin 0.0005, pH 7.4. Internal solution for M-current recording consisted of (in mM): K ϩ acetate 90, KC l 40, H EPES 20, MgC l 2 3 (adjusted to pH 7.3-7.4 with KOH, and 300 mOsm / l with K ϩ acetate); for C a 2ϩ current recording the solution consisted of (in mM): C sC l 30, cesium acetate 110, H EPES 10, MgC l 2 1 (pH 7.2-7.3 with C sOH, 300 mOsm / l). E xperiments were performed at 30 -32°C.
Voltage-clamp recordings. Data were acquired and analyzed using pC lamp software (version 6.0.3). Currents in transfected CHO cell line were recorded using Axopatch 1D patch-clamp amplifier (Axon Instruments) and filtered at 1 kHz. The capacity transients were cancelled using the resistance capacitance circuit within the amplifier. Series resistance compensation was set to 60 -80%.
SCG neurons were voltage clamped using an Axopatch 200A amplifier (Axon Instruments). Current traces were low-pass filtered at 2-5 kHz using a four-pole Bessel filter, and series resistance and membrane capacitance were partially compensated (Ͼ70%). Leak and capacitance currents were subtracted digitally using the P/6 subtraction procedure of Pclamp6. The capacity transients were cancelled using the resistance capacitance circuit within the amplifier. Series resistance compensation was also used and was set to 60 -80%.
The data were analyzed using the C lampfit (pC lamp6 and 7), ORI-GI N 5, and E xcel data handling and graphical presentation software packages. The methods of recording and analysis were similar to those used previously for studying KC NQ currents (Selyanko et al., 2000b) . Results are presented as the mean Ϯ SEM. Activation curves were fitted by the Boltzmann equation:
where I is the tail current recorded at Ϫ120 mV after a pre-step to membrane potential V (estimated from the amplitudes of exponentials backfitted to the beginning of the test step), I(50) is the current after a step to ϩ50 mV, V 1/2 is the membrane potential at which I is equal to one-half I(50), and k is the slope of the curve. The concentrationresponse of different KC NQ channels to retigabine was estimated by the shift in the V 1/2 values caused by 0.1, 0.3, 1, 3, 10, 30, 100, and 300 M. Dose -response curves were fitted to the following equation:
where EC 50 is the concentration corresponding to half-maximal activity, x is the agonist concentration, and p is the slope of the curve. Inhibition of the KC NQ1 current was evaluated by the decrease in current amplitude after step depolarizations to ϩ50 mV from Ϫ70 mV after addition of 3, 10, 30, 100, 300, and 1000 M of retigabine. The inhibition curve was fitted with Equation 2, with IC 50 concentration corresponding to half-maximal block.
Chemicals and drugs. cDNAs for human KC NQ2 and rat KC NQ3 were obtained from Dr. Figure 1 illustrates the effect of 10 M retigabine on currents carried by heteromeric KCNQ2/3 channels and homomeric KCNQ2, KCNQ3, and KCNQ4 channels expressed in CHO cells. In these experiments, an "M-current protocol" (Adams and Brown, 1982) was used to record the expressed currents; that is, the cell was predepolarized to Ϫ20 mV to activate the current, then hyperpolarized to Ϫ90 mV in steps of 10 mV to deactivate the current. Deactivation is registered by the slow tail currents, and reactivation is registered on stepping back to Ϫ20 mV by the slow outward current. The following points emerge from this comparison. (1) No appreciable current could be recorded from control (untransfected) cells, and retigabine had no significant effect on these cells (Fig. 1 B) . (2) As predicted from the previous experiments of Main et al. (2000) , Rundfeldt and Netzer (2000) , and Wickenden et al. (2000) , retigabine increased the outward current recorded at Ϫ20 mV in cells transfected with KCNQ2 ϩ KCNQ3 cDNAs. However, it also increased the Ϫ20 mV current in cells transfected solely with KCNQ2, KCNQ3, or KCNQ4 cDNAs to comparable (or greater) extents. (3) The additional current at Ϫ20 mV induced by retigabine in KCNQ2-and KCNQ2/3-transfected cells was removed by hyperpolarizing to Ϫ90 mV. However, an additional component of inward current was recorded at Ϫ90 mV in KCNQ3-and KCNQ4-transfected cells. This implies that a component of KCNQ3 or KCNQ4 current persisted in the presence of retigabine negative to resting potentials (Ϫ60 mV) (Selyanko et al., 2000b) , where these channels would normally be fully deactivated. (4) As also reported previously for KCNQ2/3 currents (Main et al., 2000; Rundfeldt and Netzer, 2000; Wickenden et al., 2000) and KCNQ3/5 currents (Wickenden et al., 2001) , retigabine slowed the deactivation of the currents during step-hyperpolarizations and accelerated the reactivation on repolarization. This effect was most pronounced with KCNQ3, for which the time dependence of current deactivation was lost except at very negative potentials, and the effect was least pronounced for KCNQ4. Thus, these tests indicate that the previously reported enhancing effect of retigabine on KCNQ2/3 and KCNQ3/5 channels also extends to homomeric KCNQ2, KCNQ3, and KCNQ4 channels, albeit with quantitative differences (see further below).
RESULTS

Retigabine enhances KCNQ2-4 currents in CHO cells
Augmentation of KCNQ2-4 currents by retigabine was confirmed after current activation from Ϫ70 mV to ϩ50 mV in 10 mV steps (Figs. 2, 3 ). Several points are worth noting. First, retigabine clearly accelerated the onset of all currents, but most noticeably with KCNQ3. Second, current-voltage curves were shifted to the left (Fig. 3) . For KCNQ2, KCNQ4, and KCNQ2/3, this corresponded to a ϳ20 -30 mV negative shift in threshold for current activation. For KCNQ3 the shift was much greater because the current was still active at the holding potential (Ϫ70 mV): in effect, retigabine converted the KCNQ3 current from a time-and voltage-dependent current with a threshold of Ϫ50 mV to a substantially time-and voltage-independent "leak" current from Ϫ90 mV upward. Third, retigabine clearly increased the maximal current generated by KCNQ3 and KCNQ4 channels (and to varying extents, by KCNQ2/3 channels) but not by KCNQ2 channels. Variation in the amount by which retigabine increased the maximum current amplitude through different KCNQ channels may reflect a variable component of secondary blocking action at positive potentials (see KCNQ1 below). Activation of heteromeric KCNQ2/3 and homomeric KCNQ2-4 channels expressed in CHO cells in the absence and presence of retigabine. Families of KCNQ currents were recorded in the absence (left) or presence (right) of 10 M retigabine. Currents were activated by 1 sec depolarizing pulses in 10 mV increments to ϩ50 mV from a holding potential of Ϫ70 mV. Records show currents recorded at Ϫ40, Ϫ20, 0, and ϩ20 mV. Note that KCNQ3 and KCNQ4, but not KCNQ2/3 and KCNQ2 currents, are increased at all voltages by retigabine.
Retigabine shifts KCNQ activation curves
The current-voltage curves in Figure 3 suggest that one effect of retigabine is to produce a negative shift in the KCNQ current activation curve. This was further tested using the protocol shown in Figure 4 , in which the current was first fully activated by stepping to ϩ50 mV, then stepped for 1 sec to various potentials between ϩ50 and Ϫ110 mV, followed by a final step to Ϫ120 mV (Fig. 4 A) . The relative amount of conductance activated at each potential at the end of the 1 sec step could then be determined directly from the residual tail-current at Ϫ120 mV. Boltzmann plots (Fig. 4 B) (see Materials and Methods) confirmed that 10 M retigabine produced a significant left-shift of the activation curves in the order KCNQ3 (Ϫ43 mV) Ͼ KCNQ2/3 (Ϫ30 mV) Ͼ KCNQ2 (Ϫ24 mV) ϾKCNQ4 (Ϫ14 mV). (Values in brackets give mean shift in half-activation potential V 1/2 .) In contrast, the slopes of the activation curves were not significantly changed by retigabine (Fig. 4, legend) .
The differential effects shown in Figure 4 were obtained using a fixed (10 M) concentration of retigabine. To measure the potency of retigabine, the shift in the activation curves produced by incremental concentrations of retigabine were determined, as illustrated in Figure 5 . To amplify the inward tail currents at Ϫ120 mV (and hence improve the accuracy of the deduced activation curves), the external K ϩ concentration was raised to 25 mM for these experiments. This did not itself affect the action of Figure 3 . Effects of retigabine on the KCNQ2-4 current-voltage relationship. Normalized current values were plotted against command potential before (E) and after (F) addition of 10 M retigabine. To obtain normalized values, peak current amplitudes in response to depolarizing pulses from a holding voltage of Ϫ70 to ϩ50 mV in 10 mV increments were normalized against the maximum current amplitude at ϩ50 mV in control recordings. Retigabine shifts the threshold for channel activation and augments KCNQ current amplitude across a range of membrane potentials. Figure 4 . Effects of retigabine on the KCNQ2-4 activation curves. A, Currents were activated by depolarizing pulses to ϩ50 mV from a holding potential of Ϫ70 mV and deactivated by 1 sec hyperpolarizing pulses to various potentials between ϩ50 and Ϫ120 mV, followed by a step to Ϫ120 mV. The inset shows the tail currents recorded at Ϫ120 mV, which were used to construct the activation curves. B, Activation curves in the absence (E) and presence (F) of retigabine were obtained from tail currents as described in Materials and Methods and fitted with the Boltzmann Equation 1. The V 1/2 values were as follows: KCNQ2/3, Ϫ17.3 Ϯ 2.2 mV for control (n ϭ 9) and Ϫ47.7 Ϯ 2.7 mV for retigabine-treated cells (n ϭ 9); KCNQ2, Ϫ11.5 Ϯ 1.5 mV for control (n ϭ 16) and Ϫ35.7 Ϯ 2.1 mV for retigabine-treated cells (n ϭ 6); KCNQ3, Ϫ28.7 Ϯ 2.5 mV for control (n ϭ 7) and Ϫ71.5 Ϯ 3.1 mV for retigabine-treated cells (n ϭ 7); and KCNQ4, Ϫ12.6 Ϯ 0.7 mV for control (n ϭ 4) and Ϫ26.2 Ϯ 0.6 mV for retigabine-treated cells (n ϭ 4). Slopes were as follows: KCNQ2/3, 12.9 Ϯ 1.2 mV (control, n ϭ 9) and 11.4 Ϯ 1.3 mV (retigabine, n ϭ 5); KCNQ2, 10.9 Ϯ 0.6 mV (control, n ϭ 16) and 11.2 Ϯ 0.9 mV (retigabine, n ϭ 6); KCNQ3, 11.4 Ϯ 0.9 mV (control, n ϭ 7) and 10.9 Ϯ 0.9 mV (retigabine, n ϭ 7); and KCNQ4, 10.1 Ϯ 0.3 mV (control, n ϭ 4) and 12.1 Ϯ 1.6 mV (retigabine, n ϭ 4). The data shown are mean Ϯ SEM.
retigabine because the shift of the KCNQ2/3 activation curve produced by 10 M retigabine in 25 mM [K ϩ ] was indistinguishable from that observed in 2.5 mM [K ϩ ], which is illustrated in Figure 4 . The magnitude of the shift in the activation curves was clearly dependent on the concentration of retigabine (Fig. 5B) . The relation between the concentration of retigabine and the shift in the half-activation potential V 1/2 for the different KCNQ channels tested deduced from these experiments, and normalized to the maximum shift produced by 10 -300 M retigabine, is shown in Figure 6 . Data points could be fitted with a Hill equation (see Materials and Methods), with slope ϳ1 but EC 50 values varying from 0.6 M for KCNQ3 to 5.2 M for KCNQ4. The maximum shift of V 1/2 also varied with different KCNQ channels. The order of potency as determined from EC 50 values (KCNQ3 Ͼ KCNQ2/ 3 Ͼ KCNQ2 Ͼ KCNQ4) accords with the apparent "efficacy" as measured by the maximum shift (Table 1) .
Interaction of retigabine and linopirdine on KCNQ2/3 currents
The blocking action of the M-channel antagonist linopirdine (Lamas et al., 1997) on KCNQ2/3 currents was unaffected by the presence of retigabine. IC 50 values were 7.3 Ϯ 1.7 M (n ϭ 3) in the absence of retigabine and 11.1 Ϯ 2.3 M (n ϭ 4) in the presence of 10 M retigabine. These values were not significantly different ( p ϭ 0.27; t test). The IC 50 value in the absence of retigabine is not dissimilar from that (4.0 Ϯ 0.5 M) reported previously by Wang et al. (1998) against KCNQ2/3 currents expressed in frog oocytes. Application of retigabine led to a slowing in the rate of decline of the KCNQ tail current (inset). B, Representative activation curves for KCNQ2/3 and KCNQ4 generated in the absence (Ⅺ) and presence of 1 M (f), 3 M (OE), 10 M (F), 30 M (), 100 M (ࡗ), and 300 M (G) retigabine. For KCNQ4, 1 mM retigabine (छ) was also applied. Figure 6 . Concentration-response curves for KCNQ2/3, KCNQ2, KCNQ3, and KCNQ4. The magnitude of the leftward shift in the halfactivation potential (V 1/2 ) was calculated with each concentration of retigabine and normalized against the maximum shift. The maximum shift in the activation curve was obtained with 10 M retigabine for KC NQ2/3, KC NQ2, and KC NQ3 and with 300 M for KC NQ4. Normalized values were plotted against retigabine concentration, and the data were fitted with Equation 2 with the following parameters: EC 50 ϭ 1.9 Ϯ 0.2 M and slope ϭ 1.3 Ϯ 0.2 for KC NQ2/3 (n ϭ 5); EC 50 ϭ 2.5 Ϯ 0.6 M and slope ϭ 1.1 Ϯ 0.5 for KCNQ2 (n ϭ 5); EC 50 ϭ 0.6 Ϯ 0.3 M and slope ϭ 1.2 Ϯ 0.4 for KCNQ3 (n ϭ 3); and EC 50 ϭ 5.2 Ϯ 0.9 M and slope ϭ 0.9 Ϯ 0.2 for KCNQ4 (n ϭ 3). Each point represents the mean Ϯ SEM.
KCNQ1 currents are resistant to enhancement by retigabine
In contrast to its effects on KCNQ2-4 currents, retigabine (10 M) did not enhance currents generated by homomeric KCNQ1 channels in CHO cells (Fig. 7A ) nor did it shift the KCNQ1 activation curve (Fig. 7C) . Instead, at positive potentials, higher concentrations of retigabine (100 M) reduced the KCNQ1 current amplitude in an apparently voltage-dependent manner, the fractional reduction increasing with increasing positivity (Fig.  7 B, D) . This effect was even more pronounced at 1 mM. The blocking action of retigabine on KCNQ1 current was quantitated by applying 3, 10, 30, 100, 300, and 1000 M retigabine and measuring the reduction of current at ϩ50 mV. Fractional inhibition of the current was plotted against retigabine concentration and points fitted with a Hill equation (see Materials and Methods), with a slope of 1.26 Ϯ 0.16 and IC 50 of 100.1 Ϯ 6.5 M (n ϭ 4) (Fig. 7E ) (note that only ϳ65% of the KCNQ1 current was inhibited with 1 mM retigabine). Retigabine had similar effects (no activation shift and partial current block at positive potentials) on currents generated by coexpressed KCNQ1 ϩ KCNE1 channels (n ϭ 4). A variable expression of the voltage-dependent inhibitory action of retigabine revealed in KCNQ1 channels may account for the variable degree of current enhancement at positive potentials through different KCNQ channels illustrated in Figure 2 .
Retigabine enhances native M currents in sympathetic neurons and shifts the voltage dependence for their activation
The native M current in rat SCG neurons has been attributed to currents carried through heteromeric KCNQ2/3 channels (Wang et al., 1998) . Hence, retigabine might be expected to affect these native M currents in a manner resembling its effect on KCNQ2/3 channels. In the present experiments we therefore recorded native M currents in dissociated rat SCG neurons using the perforated-patch configuration of the patch pipette (see Materials and Methods). Figure 8 illustrates the effect of 10 M retigabine on the outward currents evoked in a dissociated rat SCG neuron by 1 sec depolarizing steps from Ϫ80 mV. In the absence of retigabine, activation of M current is manifest by the appearance of a slow time-dependent component of outward current at command potentials of Ϫ50 mV and upward, subsequent to the transient (ϳ50 -100 msec duration) "A-current" (Fig. 8 A) . In the presence of retigabine, two differences are seen: the time-dependent component appears at a more negative command potential (Ϫ70 mV), Ϫ42.8 0.6 Ϯ 0.3 (n ϭ 3) KCNQ4 Ϫ24.6 5.2 Ϯ 0.9 (n ϭ 3)
Columns show the maximum leftward shift of V 1/2 (see Fig. 5 ) induced by retigabine and the corresponding EC 50 value for the shift for KCNQ2-4 (see Fig. 6 ), calculated as the mean Ϯ SEM of the shifts produced in the individual experiments (number of experiments in parentheses). Note that 100 M retigabine was sufficient to produce a maximum shift for KCNQ2/3, KCNQ2, and KCNQ3; for KCNQ4, 300 M retigabine was required. a KCNQ1, IC 50 for inhibition (see Fig. 7 ).
Figure 7. Retigabine does not enhance KCNQ1 current in CHO cells. A, KCNQ1 currents were recorded using the protocol shown in inset in the absence (left) and presence (right) of 10 M retigabine. B, Normalized current-voltage curve for KCNQ1 in the absence (E) and presence (F) of 100 M retigabine. Voltage protocol as in Figure 2 . Note the reduction of peak current in the presence of retigabine. C, Activation curves were constructed for KCNQ1 in the absence (E, n ϭ 11) and presence (F, n ϭ 5) of 100 M retigabine as described in Figure 4 . Lines are Boltzmann fits to the data, giving V 1/2 ϭ Ϫ12.5 Ϯ 1.1 mV and slope of 12.4 Ϯ 0.9 mV for control and V 1/2 ϭ Ϫ13.2 Ϯ 1.2 mV and slope of 12.4 Ϯ 0.9 mV in the presence of retigabine. and the total outward current is increased at all command potentials. The extra current induced by retigabine is indicated by the subtracted currents in Figure 8 B: this current is clearly "M-like" in appearance, with slow activation and deactivation, and saturates at Ϫ30 mV. Note that unlike the raw currents, the subtracted current is devoid of an initial transient A-current component, implying that the A-current was not enhanced by retigabine. The effect of retigabine on the current-voltage curves for the native M current was further examined by applying slow voltage ramps in the presence and absence of the M current blocker linopirdine (10 M) (Fig. 9A) . In this way, the component of outward rectification in the current-voltage curves attributable to M current could be identified as that component of current blocked by linopirdine (Fig. 9B) . In the presence of retigabine, this component of rectification was shifted ϳ20 mV in the negative direction (mean, Ϫ21 Ϯ 2 mV; n ϭ 5). As a result, the threshold for the outwardly rectifying M current was shifted from between Ϫ50 and Ϫ60 mV to approximately Ϫ80 mV. However, a small component of linopirdine-sensitive outward current, which appeared insensitive to voltage, could also be detected at potentials negative to Ϫ80 mV in the presence of retigabine. This was confirmed in the form of a persistent inward current on raising external [K ϩ ] to 20 mM (Fig. 9C) . As with expressed KCNQ2/3 and KCNQ2 channels (Fig. 3) , retigabine did not increase the maximum amplitude of the linopirdine-sensitive component of current. Thus, the effects of retigabine on the linopirdine-sensitive (presumed M) component of current, a negative shift in the current-voltage curve without increased maximum, were in qualitative agreement with its effects on expressed KCNQ2/3 channels. (Although the concentration of linopirdine used in these experiments was unlikely to have completely blocked the M current, the fraction blocked was presumably the same in the absence and presence of retigabine, because retigabine did not affect the action of linopirdine on expressed KNCQ2/3 currents; see above.) Enhancement of M current in SCG neurons was confirmed using the standard M-current protocol, in which M current is recorded in isolation from inactivating currents by predepolariz- ing to Ϫ20 mV and then deactivating the M current by step hyperpolarization to Ϫ50 mV ( Fig. 10; compare Fig. 1 ). Incremental addition of increasing concentrations of retigabine produced a progressive increase in the steady outward current at Ϫ20 mV, with an EC 50 of ϳ0.76 M (Fig. 10 B) (mean 0.74 Ϯ 0.02 M; n ϭ 5). There was also an increase in the residual SCG M current at Ϫ50 mV, implying that the hyperpolarizing step no longer fully deactivated the M current (as expected from the negative shift of the activation curve). These experiments also revealed that retigabine slowed the deactivation of the M current at Ϫ50 mV, the time constant for the faster component of the relaxation being slowed from ϳ30 to ϳ80 msec (Fig. 11) .
The retigabine-enhanced M current is sensitive to inhibition by muscarinic receptor agonists
The native M current in rat SCG neurons is inhibited by stimulating endogenous M 1 muscarinic receptors (Marrion et al., 1989; Bernheim et al., 1992) . We therefore tested whether the retigabine-modified M current was also sensitive to muscarinic receptor stimulation. As shown in Figure 11 , this appeared to be the case: retigabine (10 M) augmented the outward current recorded at Ϫ20 mV, and subsequent addition of the muscarinic receptor agonist Oxo-M (10 M) eliminated this extra current. The inhibitory effect of Oxo-M was quantitated by measuring the initial amplitude of the deactivation tail currents at Ϫ50 mV recorded in the presence of incrementing concentrations of Oxo-M in the absence and presence of retigabine. As indicated in Figure 12 A, the IC 50 values for Oxo-M were similar in the presence and absence of retigabine. However, the maximum inhibition produced by Oxo-M (30 M) was reduced by ϳ25%. This was unlikely to have been caused by an effect (noncompetitive) of retigabine on the muscarinic receptors because retigabine did not reduce the effect of Oxo-M on the Ca 2ϩ current recorded in pertussis toxin-treated cells (Fig. 12 B) , which is mediated by M 1 receptor activation (Bernheim et al., 1992; Delmas et al., 1998b) . Hence, although equally sensitive to Oxo-M in terms of IC 50 values, retigabine-modified M currents appear Figure 10 . Modulation of the M current by retigabine is concentration dependent. A, Superimposed M-current traces before and after cumulative addition of retigabine (0.1-30 M). The M current was recorded in response to 1 sec hyperpolarizing steps from a holding potential of Ϫ20 to Ϫ50 mV followed by a ramp to Ϫ90 mV. Note that the increase in holding current is associated with alteration of M-current deactivation relaxation. B, Holding current at Ϫ50 and Ϫ20 mV plotted against retigabine concentrations for the cell illustrated in A. Solid lines represent best fits to the Hill equation with holding currents in the absence of retigabine of 610 pA at Ϫ20 mV and 42 pA at Ϫ50 mV (as indicated by arrows). EC 50 values and Hill coefficient (slope) are indicated. Mean values are given in Results. somewhat less susceptible to muscarinic receptor modulation in terms of the amount of inhibition. One additional point emerging from these experiments was that the current-enhancing effect of retigabine was more rapid in onset than the current-inhibiting effect of Oxo-M when the two were applied simultaneously (Fig.  11 A, inset) . This implies that retigabine has a more direct effect on the M channels than Oxo-M, the action of which involves a diffusible second messenger (Selyanko et al., 1992) .
Selectivity of retigabine action on rat SCG neurons
As pointed out in connection with Figure 8 above, retigabine (10 M) had no significant effect on the transient "A-type" current recorded in rat SCG neurons (n ϭ 12), which is probably mediated by Kv4.2 K ϩ channels (Malin and Nerbonne, 2000) . Likewise, 10 M retigabine did not affect the hyperpolarizationactivated cation current I h (n ϭ 4) (Lamas, 1998) or the N-type Ca 2ϩ current (n ϭ 6). However, it did exert a small (20 Ϯ 2%; n ϭ 4) inhibitory effect on the Ca 2ϩ -activated K ϩ current driving the post-spike after-hyperpolarization.
Physiological consequences of retigabine action
Because the M current acts as a braking current on action potential discharges (Brown, 1988) , retigabine might be expected to reduce spike activity. Figure 13 illustrates a test for this on an SCG neuron. In Figure 13A , the neuron was challenged with 0.5 sec depolarizing or hyperpolarizing current injections from a resting membrane potential of approximately Ϫ60 mV. The depolarizing pulses typically evoked a phasic discharge of one or two spikes. The application of retigabine (3 M) hyperpolarized the cells by Ϫ9 Ϯ 4 mV (n ϭ 7). When the membrane potential was brought back to Ϫ60 mV, the original depolarizing current injections no longer induced spikes (Fig. 13B ). This occurs because the increase of M current conductance exerts a more effective brake on firing, as evidenced by the appearance of hyperpolarizing sags during depolarization (Fig. 13B) . Retigabine also decreased the voltage response to hyperpolarizing current pulses, as expected from an increase in cell conductance, but had no effect on action potential size or shape (Fig. 13D) .
DISCUSSION
The present experiments show that the previously described property of retigabine to enhance K ϩ currents through heteromeric KCNQ2/3 channels (Main et al., 2000; Rundfeldt and Netzer, 2000; Wickenden et al., 2000) and KCNQ3/5 channels (Wickenden et al., 2001 ) also extends to currents through homomeric KCNQ2 and KCNQ3 channels, and through the homologous KCNQ4 channels. Available information suggests that the homomeric KCNQ5 channels (Lerche et al., 2000; Schroeder et al., 2000) are also sensitive to retigabine (B. Jensen, personal communication). In contrast, the cardiac KCNQ1 channels, expressed either homomerically or as heteromeric assemblies with their natural cardiac subunit KCNE1, appear to be insensitive to the current-enhancing action of retigabine. Hence, current enhancement by retigabine is confined to neurally expressed KCNQ channels.
In agreement with Wickenden et al. (2000 Wickenden et al. ( , 2001 , we find that the principal action of retigabine is to produce a shift in the Figure 12 . Retigabine-enhanced M currents are more resistant to modulation. A, Concentration dependence of M-current inhibition by Oxo-M in the presence (F) or absence (E) of retigabine (10 M). B, Concentration dependence of Ca 2ϩ current inhibition by Oxo-M in the presence (F) or absence (E) of retigabine (10 M). Ca 2ϩ currents were recorded using the perforated-patch method in cells pretreated with pertussis toxin (0.5 g/l) for 24 hr (Delmas et al., 1998a) . Points were fitted with Equation 2 (see Materials and Methods). Figure 13 . Retigabine abolishes firing in SCG neurons. Voltage responses to depolarizing and hyperpolarizing current pulses recorded from an SCG neuron before ( A) and during the application of retigabine (RTG; 3 M) (B, C). Note in C that larger depolarizing current pulses are required to evoke an action potential in the presence of retigabine. D, Action potential evoked by a 1 msec/700 pA depolarizing pulse in the presence (thick line) and absence (thin line) of retigabine (3 M).
